A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura. Expert Rev Hematol. 2020 Sep 02;: Authors: Gómez-Seguí I, Fernández-Zarzoso M, de la Rubia J Abstract INTRODUCTION: Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy caused by inhibitory autoantibodies against ADAMTS13 protein. Until recently, the combination of plasma exchange (PEX) and immunosuppression has been the standard front-line treatment in this disorder. However, aTTP-related mortality, refractoriness, and relapse are still a matter of concern. AREAS COVERED: The better understanding of the pathophysiological mechanisms of aTTP has allowed substantial improvements in the diagnosis and treatment of this disease. Recently, the novel anti-VWF nanobody caplacizumab has been approved for acute episodes of aTTP. Caplacizumab is capable to block the adhesion of platelets to VWF, therefore inhibiting microthrombi formation in the ADAMTS13-deficient circulation. In this review, the characteristics of caplacizumab together with the available data of its efficacy and safety in the clinical setting will be analyzed. Besides, the current scenario of aTTP treatment will be provided, including the role of other innovative drugs. EXPERT OPINION: With no doubt, caplacizumab is going to change the way we treat aTTP, In combination with standard treatment, caplacizumab can help to signi...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research